Loading...
Loading...
GKOS| Name | Value |
|---|---|
| Revenues | 95.7M |
| Cost of Revenue | 22.6M |
| Gross Profit | 73.1M |
| Operating Expense | 100.6M |
| Operating I/L | -27.5M |
| Other Income/Expense | -20.2M |
| Interest Income | 2.8M |
| Pretax | -50.2M |
| Income Tax Expense | 0.3M |
| Net Income/Loss | -50.5M |
Glaukos Corporation is a leading ophthalmic medical technology and pharmaceutical company specializing in the development of innovative therapies for glaucoma, corneal disorders, and retinal diseases. The company's primary revenue comes from its range of micro-bypass stents, including iStent, iStent inject, and iStent inject W, which are inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Additionally, Glaukos Corporation generates income from its product pipeline, which includes iStent Infinite, a three-stent product for refractory glaucoma, and iDose TR, an injectable implant designed to deliver therapeutic medication levels. The company markets its products through direct sales and international distributors.
